Literature DB >> 23851696

Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival.

Felix Bock1, Susanne Rössner, Jasmine Onderka, Matthias Lechmann, Maria Teresa Pallotta, Francesca Fallarino, Louis Boon, Charles Nicolette, Mark A DeBenedette, Irina Y Tcherepanova, Ursula Grohmann, Alexander Steinkasserer, Claus Cursiefen, Elisabeth Zinser.   

Abstract

Modulation of immune responses is one of the main research aims in transplant immunology. In this study, we investigate the local immunomodulatory properties of soluble CD83 (sCD83) at the graft-host interface using the high-risk corneal transplantation model. In this model, which mimics the inflammatory status and the preexisting vascularization of high-risk patients undergoing corneal transplantation, allogeneic donor corneas are transplanted onto sCD83-treated recipient animals. This model allows the direct and precise application of the immune modulator at the transplantation side. Interestingly, sCD83 was able to prolong graft survival after systemic application as well as after topical application, which is therapeutically more relevant. The therapeutic effect was accompanied by an increase in the frequency of regulatory T cells and was mediated by the immune-regulatory enzyme IDO and TGF-β. In vitro, sCD83 induced long-term IDO expression in both conventional and plasmacytoid dendritic cells via autocrine or paracrine production of TGF-β, a cytokine previously shown to be an essential mediator of IDO-dependent, long-term tolerance. These findings open new treatment avenues for local immune modulation after organ and tissue transplantation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23851696     DOI: 10.4049/jimmunol.1201531

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  L Particles Transmit Viral Proteins from Herpes Simplex Virus 1-Infected Mature Dendritic Cells to Uninfected Bystander Cells, Inducing CD83 Downmodulation.

Authors:  Christiane S Heilingloh; Mirko Kummer; Petra Mühl-Zürbes; Christina Drassner; Christoph Daniel; Monika Klewer; Alexander Steinkasserer
Journal:  J Virol       Date:  2015-08-26       Impact factor: 5.103

2.  Putative loss of CD83 immunosuppressive activity in long-standing complication-free juvenile diabetic patients during disease progression.

Authors:  Ulana Juhas; Monika Ryba-Stanisławowska; Urszula Ławrynowicz; Małgorzata Myśliwiec; Jolanta Myśliwska
Journal:  Immunol Res       Date:  2019-02       Impact factor: 2.829

3.  Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.

Authors:  Joe M Horvatinovich; Elizabeth W Grogan; Marcus Norris; Alexander Steinkasserer; Henrique Lemos; Andrew L Mellor; Irina Y Tcherepanova; Charles A Nicolette; Mark A DeBenedette
Journal:  J Immunol       Date:  2017-02-13       Impact factor: 5.422

4.  Effect of bone marrow-derived CD11b(+)F4/80 (+) immature dendritic cells on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis.

Authors:  Jingjing Fu; Lingling Zhang; Shanshan Song; Kangliang Sheng; Ying Li; Peipei Li; Shasha Song; Qingtong Wang; Jianhong Chu; Wei Wei
Journal:  Inflamm Res       Date:  2014-01-24       Impact factor: 4.575

5.  CD83 expression is essential for Treg cell differentiation and stability.

Authors:  Marina Doebbeler; Christina Koenig; Lena Krzyzak; Christine Seitz; Andreas Wild; Thomas Ulas; Kevin Baßler; Dmitry Kopelyanskiy; Alina Butterhof; Christine Kuhnt; Simon Kreiser; Lena Stich; Elisabeth Zinser; Ilka Knippertz; Stefan Wirtz; Christin Riegel; Petra Hoffmann; Matthias Edinger; Lars Nitschke; Thomas Winkler; Joachim L Schultze; Alexander Steinkasserer; Matthias Lechmann
Journal:  JCI Insight       Date:  2018-06-07

6.  Induction of indoleamine 2,3-dioxygenase by Borrelia burgdorferi in human immune cells correlates with pathogenic potential.

Authors:  Andrea C Love; Ira Schwartz; Mary M Petzke
Journal:  J Leukoc Biol       Date:  2014-11-24       Impact factor: 4.962

7.  Soluble CD83 ameliorates experimental colitis in mice.

Authors:  J Eckhardt; S Kreiser; M Döbbeler; C Nicolette; M A DeBenedette; I Y Tcherepanova; C Ostalecki; A J Pommer; C Becker; C Günther; E Zinser; T W Mak; A Steinkasserer; M Lechmann
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

8.  CD83 orchestrates immunity toward self and non-self in dendritic cells.

Authors:  Andreas B Wild; Lena Krzyzak; Katrin Peckert; Lena Stich; Christine Kuhnt; Alina Butterhof; Christine Seitz; Jochen Mattner; Niklas Grüner; Maximilian Gänsbauer; Martin Purtak; Didier Soulat; Thomas H Winkler; Lars Nitschke; Elisabeth Zinser; Alexander Steinkasserer
Journal:  JCI Insight       Date:  2019-10-17

9.  Human Indoleamine 2,3-dioxygenase 1 (IDO1) Expressed in Plant Cells Induces Kynurenine Production.

Authors:  Michele Bellucci; Andrea Pompa; Carine De Marcos Lousa; Eleonora Panfili; Elena Orecchini; Elisa Maricchiolo; Daniele Fraternale; Ciriana Orabona; Francesca De Marchis; Maria Teresa Pallotta
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

10.  Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease.

Authors:  Bishwas Shrestha; Kelly Walton; Jordan Reff; Elizabeth M Sagatys; Nhan Tu; Justin Boucher; Gongbo Li; Tayyebb Ghafoor; Martin Felices; Jeffrey S Miller; Joseph Pidala; Bruce R Blazar; Claudio Anasetti; Brian C Betts; Marco L Davila
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.